Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor‐naïve patients with myelofibrosis: Results of a phase II trial

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure

(2020) Claire N. Harrison et al.   AMERICAN JOURNAL OF HEMATOLOGY

Management of myelofibrosis after ruxolitinib failure

(2020) Claire N Harrison et al.   ANNALS OF HEMATOLOGY

The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib

(2020) Anand A. Patel et al.   Current Hematologic Malignancy Reports

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Tolerance, Pharmacokinetics of Jaktinib, a New Selective Janus Kinase Inhibitor in Healthy Chinese Volunteers

(2020) Jingrui Liu et al.   Frontiers in Pharmacology

Momelotinib for the treatment of myelofibrosis

(2019) Li Xu et al.   EXPERT OPINION ON PHARMACOTHERAPY

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis

(2019) Jan Philipp Bewersdorf et al.   Cancer Management and Research

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

(2018) Tiziano Barbui et al.   LEUKEMIA

Management of Myelofibrosis-Related Cytopenias

(2018) Prithviraj Bose et al.   Current Hematologic Malignancy Reports

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

(2018) Claire N Harrison et al.   Lancet Haematology

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis

(2018) John Mascarenhas et al.   JAMA Oncology

Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management

(2018) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

(2017) Ruben A. Mesa et al.   JOURNAL OF CLINICAL ONCOLOGY

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

(2017) Ruben A Mesa et al.   Lancet Haematology

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

(2016) C N Harrison et al.   LEUKEMIA

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

(2015) S. Verstovsek et al.   HAEMATOLOGICA

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

(2015) S. Verstovsek et al.   HAEMATOLOGICA

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis

(2015) Animesh Pardanani et al.   JAMA Oncology

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE